# A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

> **NCT05612581** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** VIR-3434
- **DRUG:** VIR-2218
- **DRUG:** TDF
- **DRUG:** PEG-IFNα

## Key facts

- **NCT ID:** NCT05612581
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2024-10-15
- **Final completion:** 2025-08-19
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05612581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05612581, "A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05612581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*